When Radiotherapy and Immunotherapy Dance—Who Leads So as Not to Step on Toes?
Menée à partir de données de la "US Food and Drug Administration" portant sur 16 835 patients atteints d'un cancer, cette étude analyse le risque d'événements indésirables graves lorsqu'une radiothérapie est administrée dans les 90 jours précédant un traitement par inhibiteur de point de contrôle immunitaire
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several cancers, significantly increasing survival in advanced disease. A substantial proportion of these patients have received radiotherapy (RT) prior to or after ICI treatment. We have aggressively moved toward strategies combining RT and immunotherapy concurrently or sequentially in oligometastatic disease. Importantly, this strategy has gravitated to earlier stages of disease, with some outstanding successes. What have we learned about the toxicity implications associated with this combination, and how might we mitigate harm to the patient?
JAMA Oncology , éditorial, 2021